EULAR recommendations for the managements of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 Update;Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013

Rheumatologia

Volumn 28, Issue 1, 2014, Pages 1-25

  Smolen, J S ^a,b   Landewe R ^c,d   Breedveld, F C ^e   Buch, M ^f,g   Burmester, G ^h,i   Dougados, M ^j   Emery, P ^f,g   Gaujoux Viala, C ^k   Gossec, L ^l   Nam, J ^f,g   Ramiro, S ^c,m   Winthrop, K ⁿ   De Wit, M ^o   Aletaha, D ^a   Betteridge, N ^o   Bijlsma, J W J ^p   Boers, M ^q   Buttgereit, F ^h,i   Combe, B ^r   Cutolo, M ^s   Damjanov, N ^t   Hazes, J M W ^u   Kouloumas, M ^o   Kvien, T K ^v   Mariette, X ^w   Pavelka, K ^x   Van Riel, P L C M ^y   Rubbert Roth, A ^z   Scholte Voshaar, M ^o   Scott, D L ^aa   Sokka Isler, T ^ab,ac   Wong, J B ^ad   Van Der Heijde, D ^e   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital Vienna   (Austria)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ HUMBOLDT UNIVERSITY   (Germany)

^j Department of Rheumatology B Cochin Hospital René Descartes University ^*  (France)

^k NÎMES UNIVERSITY HOSPITAL   (France)

^l SORBONNE UNIVERSITÉ   (France)

^m HOSPITAL GARCIA DE ORTA   (Portugal)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE)   (Switzerland)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIV MONTPELLIER   (France)

^s UNIVERSITY OF GENOA   (Italy)

^t UNIVERSITY OF BELGRADE   (Serbia)

^u ERASMUS MEDICAL CENTER   (Netherlands)

^v DIAKONHJEMMET HOSPITAL   (Norway)

^w ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^x CHARLES UNIVERSITY   (Czech Republic)

^y RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^z UNIVERSITY OF COLOGNE   (Germany)

^aa KING'S COLLEGE LONDON   (United Kingdom)

^ab JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^ac Finland MedCare Ltd   (Finland)

^ad TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biological antirheumatic drugs; Disease modifying antirheumatic drugs; EULAR recommendations; Managements of rheumatoid arthritis; Synthetic antirheumatic drugs

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CONSENSUS DEVELOPMENT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; PATIENT DECISION MAKING; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC);

EID: 84901930157     PISSN: 12101931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Smolen, J.S., Aletaha, D., Koeller, M. a spol.: New therapies for the treatment of rheumatoid arthritis. Lancet, 370, 2007, s. 1861-1874.
2. Smolen, J.S., van der Heijde, D., Machold, K.P. a spol.: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis, 2013. Published Online First: 26 Sep 2013. doi:10.1136/annrheumdis-2013-204317.
3. Smolen, J.S., Landewe, R., Breedveld, F.C. a spol.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 69, 2010, s. 964-975.
4. Gaujoux-Viala, C., Smolen, J.S., Landewe, R. a spol.: Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 69, 2010, s. 1004-1009.
5. Nam, J.L., Winthrop, K.L., van Vollenhoven, R.F. a spol.: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis, 69, 2010, s. 976-986.
6. Gorter, S.L., Bijlsma, J.W., Cutolo, M. a spol.: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 69, 2010, s. 1010-1014.
7. Knevel, R., Schoels, M., Huizinga, T.W. a spol.: Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 69, 2010, s. 987-994.
8. Schoels, M., Wong, J., Scott, D.L. a spol.: Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Arm Rheum Dis, 69, 2010, s. 995-1003.
9. Mok, C.C., Tam, L.S., Chan, T.H. a spol.: Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol, 30, 2011, s. 303-312.
10. El Zorkany, B., Alwahshi, H.A., Hammoudeh, M. a spol.: Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol, 32, 2013, s. 151-159.
11. Wollenhaupt, J., Albrecht, K., Kruger, K. a spol.: The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint. Z Rheumatol, 72, 2013, s. 6-9.
12. Bykerk, V.P., Akhavan, P., Hazlewood, G.S. a spol.: Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol, 39, 2012, s. 1559-1582.
13. Gaujoux-Viala, C., Nam, J.L., Ramiro, S. a spol.: Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2013; submitted.
14. Nam, J.L., Ramiros, S., Gaujoux-Viala, C. a spol.: 2013 update of the evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management RA. Ann Rheum Dis 2013; submitted.
15. Ramiro, S., Gaujoux-Viala, C., Nam, J.L. a spol.: Safety of synthetic and biological DMARDs - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2013; submitted.
16. OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based Medicine. The Oxford 2011 Levels of Evidence, 2011. Ref Type: Grant
17. Widdifield, J., Bernatsky, S., Paterson, J.M. a spol.: Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken), 63, 2011, s. 53-57.
18. Bonafede, M.M., Fox, K.M., Johnson, B.H. a spol.: Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther, 34, 2012, s. 457-467.
19. van Eijk-Hustings, Y., van T.A., Bostrom, C. a spol.: EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis, 71, 2012, s. 13-19.
20. Peters, M.J., Symmons, D.P., McCarey, D. a spol.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis, 69, 2010, s. 325-331.
21. Lundkvist, J., Kastäng, F., Kobelt, G.: The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ, 8, 2008, Suppl. 2, s. S49-60.
22. Murray, C.J., Vos, T., Lozano, R. a spol.: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2012, s. 2197-2223.
23. Vos, T., Flaxman, A.D., Naghavi, M. a spol.: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2012, s. 2163-2196.
24. Kobelt, G., Jönsson, B.: The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ, 8, 2008, Suppl. 2, s. S95-106.
25. Kärrholm, J., Garelick, G., Herberts, P.: Swedish Hip reaplecement Register - Annual Report 2006. 2008. http://www.jruorthopguse/ (accessed 23 Aug 2008).
26. Schoels, M., Aletaha, D., Smolen, J.S. a spol.: Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis, 2012.
27. Schiff, M., Fleischmann, R., Weinblatt, M. a spol.: Abatacept sc versus adalimumab on background methotrexate in RA: one year results from the AMPLE study. Ann Rheum Dis, 71, 2012, Suppl. 3, s. 60.
28. Gabay, D.C., Emery, P., van Vollenhoven, R. a spol.: Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (ra): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis, 71, 2012, Suppl. 3, s. 152.
29. van Vollenhoven, R.F., Ernestam, S., Geborek, P. a spol.: Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet, 374, 2009, s. 459-466.
30. van der, K.E., Klarenbeek, N.B., Guler-Yuksel, M. a spol.: A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study. Ann Rheum Dis, 70, 2011, s. 168-171.
31. Dorner, T., Strand, V., Castaneda-Hernandez, G. a spol.: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis, 72, 2013, s. 322-328.
32. Radner, H., Neogi, T., Smolen, J.S. a spol.: Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis, 72, 2013.
33. Smolen, J.S., Aletaha, D., Bijlsma, J.WJ. a spol.: Treating rheumatoid arthritis to target: recommendations of an international task force. Arm Rheum Dis, 69, 2010, s. 631-637.
34. Felson, D.T., Smolen, J.S., Wells, G. a spol.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis, 70, 2011, s. 404-413.
35. Kavanaugh, A., Fleischmann, R.M., Emery, P. a spol.: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis, 72, 2013, s. 64-71.
36. Gabay, C., Emery, P., van V.R. a spot.: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet, 381, 2013, s. 1541-1550.
37. Mierau, M., Schoels, M., Gonda, G. a spol.: Assessing remission in clinical practice. Rheumatology, 46, 2007, s. 975-979.
38. Klarenbeek, N.B., Koevoets, R., Van der Heijde, D.M. a spol.: Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Arm Rheum Dis, 70, 2011, s. 1815-1821.
39. Koevoets, R., van der Heijde, D.: Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis Rheum, 60, 2009, Suppl., s. 957.
40. Smolen, J.S., Han, C., Van der Heijde, D.M. a spol.: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis, 68, 2009, s. 823-827.
41. Aletaha, D., Smolen, J.S.: Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum, 63, 2011, s. 3702-3711.
42. Balsa, A., de Miguel, E., Castillo, C. a spol.: Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford), 49, 2010, s. 683-690.
43. Sakellariou, G., Scire, C.A., Verstappen, S.M. a spol.: In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis, 72, 2013, s. 245-249.
44. Gartner, M., Mandl, P., Radner, H. a spol.: Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum, 65, 2013.
45. Aletaha, D., Landewe, R., Karonitsch, T. a spol.: Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis, 67, 2008, s. 1360-1364.
46. Radner, H., Smolen, J.S., Aletaha, D.: Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford), 50, 2011, s. 381-388.
47. Kiely, P., Walsh, D., Williams, R. a spol.: Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity - the early RA network (ERAN). Rheumatology (Oxford), 50, 2011, s. 926-931.
48. Montag, K., Gingold, M., Boers, A. a spol.: Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J, 41, 2011, s. 450-455.
49. Aletaha, D., Funovits, J., Keystone, E.C. a spol.: Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum, 56, 2007, s. 3226-3235.
50. Visser, K., van der Heijde, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis, 68, 2009, s. 1094-1099.
51. Aletaha, D., Martinez-Avila, J., Kvien, T.K. a spol.: Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis, 71, 2012, s. 1190-1196.
52. van Gestel, A.M., van Riel, P.L.C.M.: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum, 41, 1998 s. 1845-1850.
53. Pincus, T., Yazici, Y., Sokka, T. a spol.: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Gin Exp Rheumatol, 21, 2003, Suppl. 31), s. S178-185.
54. Aletaha, D., Funovits, J., Smolen, J.S.: The importance of reporting disease activity states in clinical trials of rheumatoid arthritis. Arthritis Rheum, 58, 2008, s. 2622-2631.
55. Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F. a spol.: The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 54, 2006, s. 26-37.
56. St Clair, E.W., van der Heijde, D.M., Smolen, J.S. a spol.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum, 50, 2004, s. 3432-3443.
57. Klareskog, L., van der Heijde, D., de Jager, J.P. a spol.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 363, 2004, s. 675-681.
58. Tak, P.P., Rigby, W.F., Rubbert-Roth, A. a spol.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis, 70, 2011, s. 39-46.
59. Westhovens, R., Robles, M., Ximenes, A.C. a spol.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis, 68, 2009, s. 1870-1877.
60. Heimans, L., Wevers-de Boer, K.V., Visser, K. a spol.: A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis, 2013. Published Online First: 28 May 2013. doi: 10.1136/annrheumdis-2013-203243
61. van Ede, A.E., Laan, R.F., Rood, M.J. a spol.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum, 44, 2001, s. 1515-1524.
62. Salliot, C., van der, H.D.: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis, 68, 2009, s. 1100-1104.
63. Burmester, G., Kivitz, A., Kupper, H. a spol.: Efficacy, pharmacokinetics, and safety of different doses of methotrexate in combination with adalimumab: results from the CONCERTO trial. Ann Rheum Dis, 72, 2013, Suppl. 3, s. 72.
64. Katchamart, W., Trudeau, J., Phumethum, V. a spol.: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis, 68, 2009, s. 1105-1112.
65. van der Heijde, D.M., van Riel, P.L., Nuver-Zwart, J. a spol.: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet, 1, 1989, s. 1036-1038.
66. Smolen, J.S., Kalden, J.R., Scott, D.L. a spol.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet, 353, 1999, s. 259-266.
67. Sharp, J.T., Strand, V., Leung, H. a spol.: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum, 43, 2000, s. 495-505.
68. Strand, V., Cohen, S., Schiff, M. a spol.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med, 159, 1999, s. 2542-2550.
69. Dougados, M., Combe, B., Cantagrel, A. a spol.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis, 58, 1999, s. 220-225.
70. Burmester, G.R., Mariette, X., Montecucco, C. a spol.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis, 66, 2007, s. 732-739.
71. Strangfeld, A., Hierse, F., Kekow, J. a spol.: Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis, 68, 2009, s. 1856-1862.
72. van Riel, P.L., van Gestel, A.M., van de Putte, L.B.: Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol, 34, 1995, Suppl. 2, s. 40-42.
73. Capell, H.A.: Clinical efficacy of sulphasalazine - a review. Br J Rheumatol, 34, 1995, Suppl. 2, s. 35-39.
74. Pullar, T., Hunter, J.A., Capell, H.A.: Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol, 24, 1985, s. 269-276.
75. Food and Drug Administration. Azulfidine EN-tabs. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/007073s1251bl.pdf (accessed 7 Sep2013).
76. Keystone, E.C., Wang, M.M., Layton, M. a spol.: Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis, 71, 2012, s. 1630-1635.
77. Ostensen, M., Forger, F.: Management of RA medications in pregnant patients. Nat Rev Rheumatol, 5, 2009, s. 382-390.
78. Pincus, T., Ferraccioli, G., Sokka, T. a spol.: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford), 41, 2002, s. 1346-1356.
79. Katz, S.J., Russell, A.S.: Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol, 23, 2011, s. 278-281.
80. Bill, A., Sartorius, J.A., Kirchner, H.L. a spol.: Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol, 17, 2011, s. 115-120.
81. Morris, S.J., Wasko, M.C., Antohe, J.L. a spol.: Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 63, 2011, s. 530-534.
82. Scherbel, A.L., Schuchter, S.L., Harrison, J.W.: Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis. Cleve Clin Q, 24, 1957, s. 98-104.
83. Gaujoux-Viala, C., Smolen, J.S., Landewe, R. a spol.: Current evidence for the management of rheumatoid arthritis with synthetic disease modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 69, 2010, s. 1004-1009.
84. van Vollenhoven, R.F., Geborek, P., Forslind, K. a spol.: Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet, 379, 2012, s. 1712-1720.
85. de Jong, P.H., Hazes, J.M., Barendregt, P.J. a spol.: Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis, 72, 2013, s. 72-78.
86. Moreland, L.W., O'Dell, J.R., Paulus, H.E. a spol.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum, 64, 2012, s. 2824-2835.
87. Leirisalo-Repo, M., Kautiainen, H., Laasonen, L. a spol.: Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis, 72, 2013, s. 851-857.
88. O'Dell, J.R., Mikuls, T.R., Taylor, T.H. a spol.: Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. N Engl J Med, 369, 2013, s. 307-318.
89. Klarenbeek, N.B., Guler-Yuksel, M., van der Kooij, S.M. a spol.: The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis, 70, 2011, s. 1039-1046.
90. De Jong, P.H.P.D., Hazes, J.M., Luime, J.J. a spol.: Randomized comparison of triple DMARD therapy with methotrexate mono-therapy. Ann Rheum Dis, 72, 2013, Suppl. 3, s. 113.
91. Graudal, N., Jurgens, G.: Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum, 62, 2010, s. 2852-2863.
92. Bakker, M.F., Jacobs, J.W., Welsing, P.M. a spol.: Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med, 156, 2012, s. 329-339.
93. Buttgereit, F., da Silva, J.A., Boers, M. a spol.: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 61, 2002, s. 718-722.
94. Svensson, B., Boonen, A., Albertsson, K. a spol.: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum, 52, 2005, s. 3360-3370.
95. Landewe, R.B., Boers, M., Verhoeven, A.C. a spol.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum, 46, 2002, s. 347-356.
96. Wassenberg, S., Rau, R., Steinfeld, P. a spol.: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 52, 2005, s. 3371-3380.
97. Goekoop-Ruiterman, Y.P., De Vries-Bouwstra, J.K., Allaart, C.F. a spol.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum, 52, 2005, s. 3381-3390.
98. Kirwan, J.R.: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med, 333, 1995, s. 142-146.
99. Bijlsma, J.W., Hoes, J.N., Van Everdingen, A.A. a spot.: Are glucocorticoids DMARDs? Ann N Y Acad Sci, 106, 2006, č. 9, s. 268-274.
100. da Silva, J.A., Jacobs, J.W., Kirwan, J.R. a spol.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis, 65, 2006, s. 285-293.
101. Hoes, J.N., Jacobs, J.W., Boers, M. a spol.: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Arm Rheum Dis, 66, 2007, s. 1560-1567.
102. Vastesaeger, N., Xu, S., Aletaha, D. a spol.: A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford), 48, 2009, s. 1114-1121.
103. Visser, K., Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K. a spol.: A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis, 69, 2010, s. 1333-1337.
104. Moreland, L.W., O'Dell, J.R., Paulus, H.E. a spol.: Two-year radiographic results from the TEAR trial. Arthritis Rheum, 62, 2010, Suppl., s. S568-569.
105. Morel, J., Duzanski, M.O., Cantagrel, A. a spol.: Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry - roactemra). Ann Rheum Dis, 72, 2013, Suppl. 3, s. 456.
106. Hishitani, Y., Ogata, A., Shima, Y. a spol.: Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol, 42, 2013, s. 253-259.
107. Horak, P., Skacelova, M., Hejduk, K. a spol.: Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin Rheumatol, 32, 2013, s. 1451-1458.
108. Gottenberg, J.E., Ravaud, P., Bardin, T. a spol.: Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum, 62, 2010, s. 2625-2632.
109. Godot, S., Gottenberg, J.E., Paternotte, S. a spol.: Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: Data from the Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken), 2013. doi: 10.1002/acr.22056. [Epub ahead of print 10 Jun 2013].
110. Weinblatt, M.E., Schiff, M., Valente, R. a spol.: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum, 65, 2013, s. 28-38.
111. Tak, P.P., Rigby, W.F., Rubbert-Roth, A. a spol.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis, 70, 2011, s. 39-46.
112. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A. a spol.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 54, 2006, s. 1390-1400.
113. Buch, M.H., Smolen, J.S., Betteridge, N. a spol.: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis, 70, 2011, s. 909-920.
114. Strangfeld, A., Pattloch, D., Herzer, P. a spol.: Risk of cancer recurrence or new tumors in RA patients with prior malignancies treated with various biologic agents. Arhritis Rheum 2013; (ACR 2013 Abstract online (https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/36584).
115. Yoo, D.H., Hrycaj, P., Miranda, P. a spol.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis, 72, 2013, s. 1613-1620.
116. Park, W., Hrycaj, P., Jeka, S. a spol.: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis, 72, 2013, s. 1605-1612.
117. Krieckaert, C.L., Nurmohamed, M.T., Wolbink, G.J.: Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis, 71, 2012, s. 1914-1915.
118. Jones, G., Sebba, A., Gu, J. a spol.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis, 69, 2010, s. 88-96.
119. Nishimoto, N., Hashimoto, J., Miyasaka, N. a spol.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 66, 2007, s. 1162-1167.
120. Burmester, G.R., Rigby, W., van Vollenhoven, R. a spol.: Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis, 72, 2013, Suppl., OP041.
121. Bakker, M.F., Jacobs, J.W., Verstappen, S.M. a spol.: Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis, 66, 2007, Suppl. 3, s. iii56-60.
122. Dougados, M., Kissel, K., Sheeran, T. a spol.: Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Arm Rheum Dis, 72, 2013, s. 43-50.
123. Emery, P., Kvien, T.K., Combe, B. a spol.: Combination etanercept and methotrexate provides better disease control in very early (d"4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis, 71, 2012, s. 989-992.
124. van Riel, P.L., Taggart, A.J., Sany, J. a spol.: Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis, 65, 2006, s. 1478-1483.
125. Soubrier, M., Puechal, X., Sibilia, J. a spol.: Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford), 48, 2009, s. 1429-1434.
126. Fleischmann, R., van Vollenhoven, R.F., Smolen, J.S. a spol.: Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Arthritis Rheum, 64, 2012, Suppl., s. S335-336.
127. Smolen, J.S., Flelschmann, R.M., Emery, P. a spol.: Treating Rheumatoid Arthritis to Target: Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate, Methotrexate Alone, or Methotrexate Plus Subsequent Adalimumab. Arthritis Rheum, 63, 2011, Suppl., s. S665.
128. Kavanaugh, A., Emery, P., Felischmann, R.M. a spol.: Withrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: esults of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford), 51, 2012, Suppl. 3, s. iii27.
129. Detert, J., Bastian, H., Listing, J. a spol.: Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis, 72, 2013, s. 844-850.
130. Emery, P., Hammoudeh, M., Fitzgerald, O. a spol.: Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study. Ann Rheum Dis, 72, 2013, Suppl. 3, s. 399.
131. Huizinga, T., Kivitz, A.J., Rell-Bakalarska, M. a spol.: Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study. Arm Rheum Dis, 71, 2012, Suppl. 3, s. 60.
132. Hsu, B., Sheng, S., Smolen, J. a spol.: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis Rheum, 63, 2011, Suppl., s. S1034.
133. Mease, P., Strand, V., Shalamberidze, L. a spol.: A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis, 71, 2012, s. 1183-1189.
134. van Vollenhoven, R.F., Fleischmann, R., Cohen, S. a spol.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med, 367, 2012, s. 508-519.
135. Burmester, G.R., Blanco, R., Charles-Schoeman, C. a spol.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet, 381, 2013, s. 451-460.
136. Fleischmann, R., Kremer, J., Cush, J. a spol.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med, 367, 2012, s. 495-507.
137. van der Heijde, D., Tanaka, Y., Fleischmann, R. a spol.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-Month data from a 24-month Phase 3 randomized radiographic study. Arthritis Rheum, 65, 2013, s. 559-570.
138. Lee, E.B., Fleischmann, R.M., Hall, S. a spol.: Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Nave Patients with Rheumatoid Arthritis. Arthritis Rheum, 64, 2012, Suppl., s. S1049.
139. Winthrop, K.L., Baddley, J.W., Chen, L. a spol.: Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. J Amer Med Ass, 309, 2013, s. 887-895.
140. Guyatt, G.H., Oxman, A.D., Kunz, R. a spol.: Incorporating considerations of resources use into grading recommendations. Brit Med J, 336, 2008, s. 1170-1173.
141. Garber, K.. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol, 31, 2013, s. 3-4.
142. Xeljanz Filmtbl 5mg (iH 08/13). 2013. http://www.kompendium.ch/prod/pnr/ 1234138/de.
143. European Medicines Agency-CHMP. Summary of Opinion (Infliximab biosimilar). 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Summary- of-opinion---Initial-authorisation/human/002576/WC500144832.pdf,editors.
144. European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. 2013. http://www.ema.europa.eu/ docs/en-GB/ document-library/Press-release/2013/06/WC500144941.pdf.
145. European Medical Agency. Xeljanz. 2013. http://www.ema.europa.eu/ema/ indexjsp?curl=pages/medicines/human/medicines/002542/smops/Negative/ human-smop-000501jsp&mid=WC0b01ac058001d127 (accessed 25 May, 2014).
146. Committee for Medicinal Products for Human Use (CHMP). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 22-25 July 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/ 2013/07/news-detail-001851.jsp&mid=WC0b01ac058004d5c1.
147. Pfizer. Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013. http://press.pfizer.com/press-release/pfizer-receives-chmp- negative-opinionregardingmarketing-authorization-europe-rheumat (accessed 25 May 2013).
148. Tanaka, Y., Hirata, S., Saleem, B. a spol.: Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol, 2013 (in press).
149. Kavanaugh, A., Smolen, J.S.: The when and how of biologics withdrawal in rheumatoid arthritis - learning from large randomized controlled trials. Clin Exp Rheumatol, 2013 (in press).
150. Tanaka, Y., Takeuchi, T., Mimori, T. a spol.: Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis, 69, 2010, s. 1286-1291.
151. Chatzidionysiou, K., Turesson, C., Teleman, A. a spol.: A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission. Arthritis Rheum, 64, 2012, Suppl., s. S336.
152. Smolen, J.S., Nash, P., Durez, P. a spol.: Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, 381, 2013, s. 918-929.
153. Klarenbeek, N.B., van der Kooij, S.M., Guler-Yuksel, M. a spol.: Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses firm the BeSt study. Ann Rheum Dis, 7, 2011, s. 315-319.
154. Smolen, J.S., Emery, P., Fleichmann, R. a spol.: Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotreate alone: the randomised controlled OPTIMA trial. Lancet, 2013 (in press).
155. Fautrel, B., Gandjbakhch, F., Foltz, V. a spol.: Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a stepdown strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis, 72, 2013, Suppl. 3, s. 72.
156. Takeuchi, T., Matsubara, T., Ohta, S. a spol.: Abatacept biologic-free remission study in established rheumatoid arthritis - ORION study. Ann Rheum Dis, 72, 2013, Suppl. 3, s. 613.
157. Nampei, A., Nagayama, Y.: Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis, 72, 2013, Suppl. 3, s. 877.
158. Batticciotto, A., Varisco, V., Antivalle, M. a spol.: Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis, 72, 2013, Suppl., s. 877.
159. Brocq, O., Millasseau, E., Albert, C. a spol.: Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine, 76, 2009, s. 350-355.
160. ten Wolde, S., Breedveld, F.C., Hermans, J. a spol.: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet, 347, 1996, s. 347-352.
161. O'Mahony, R., Richards, A., Deighton, C. a spol: Withdrawal of DMARDs in patients with Rheumatoid Arthritis: a systematic review and meta-analysis. Ann Rheum Dis, 69, 2010, s. 1823-1826.
162. van der Woude, D., Visser, K., Klarenbeek, N.B. a spol: Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford), 51, 2012, s. 1120-1128.
163. Gonzalez, A., Maradit, K.H., Crowson, C.S. a spol.: Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis, 67, 2008, s. 64-69.
164. Baecklund, E., Iliadou, A., Askling, J. a spot.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum, 54, 2006, s. 692-701.
165. Choi, H.K., Hernan, M.A., Seeger, J.D. a spol.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet, 359, 2002, s. 1173-1177.
166. Westlake, S.L., Colebatch, A.N., Baird, J. a spol: The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford), 49, 2010, s. 295-307.
167. Westlake, S.L., Colebatch, A.N., Baird, J. a spol.: Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford), 50, 2011 s. 518-531.
168. Aletaha, D., Funovits, J., Breedveld, F.C. a spol.: Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum, 60, 2009, s. 1242-1249.
169. Roux, C.H., Breuil, V., Valerio, L. a spol.: Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. J Rheumatol, 38, 2011, s. 1009-1011.
170. Dernis, E., Ruyssen-Witrand, A., Mouterde, G. a spol.: Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine, 77, 2010, s. 451-457.
171. Krieckaert, C.L., Jamnitski, A., Nurmohamed, M.T. a spol.: Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum, 64, 2012, s. 3850-3855.
172. Singh, J.A., Furst, D.E., Bharat, A. a spol.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken), 64, 2012, s. 625-639.
173. Dougados, M., Betteridge, N., Burmester, G.R. a spol.: EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis, 63, 2004, s. 1172-1176.
174. Schoels, M., Aletaha, D., Smolen, J.S. a spol.: Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis, 69, 2010, s. 575-578.
175. Stoffer, M.A., Smolen, J.S., Woolf, A. a spol.: Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis. Published Online First: 6 Aug 2013. doi: 10.1136/annrheumdis-2013-203743.